Nemaura Medical Inc
NASDAQ:NMRD
Intrinsic Value
Nemaura Medical, Inc. operates as a holding company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of NMRD.
Nemaura Medical Inc's market capitalization is 1.9m USD.
NMRD stock price is 0.065 USD.
NMRD.
NMRD. Open DCF Valuation
NMRD. Open Relative Valuation
NMRD.
NMRD's ROE (Return on Equity) has significantly increased in the last 3 years from -178% to 77%.
NMRD's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -221% to -196%, and is approaching profitability.
NMRD has negative Operating Income for the last twelve months.
NMRD has negative Net Income for the last twelve months.
NMRD's ROE (Return on Equity) for the past 12 months is very high and is equal to 77%.
NMRD's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -196%.
NMRD has negative Free Cash Flow for the last twelve months.
NMRD's long-term liabilties (23m USD) exceed its long-term assets (5m USD).
NMRD's short-term liabilties (23m USD) exceed its short-term assets (4m USD).
NMRD has negative three-year average ROE (Return on Equity): -23%. The company is not efficient at transforming stockholders' equity into net income.
NMRD has negative three-year average ROIC (Return on Invested Capital): -184%. The company is not efficient at using invested capital to generate operating income.
NMRD's D/E (Debt to Equity) is very low and is equal to 0.
NMRD's Altman Z-Score is very low and is equal to -26.2.
NMRD doesn't generate enough operating income (-10m USD) to safely cover interest payments on its debt (921k USD).
Fundamental Analysis
Nemaura Medical Inc
Balance Sheet Decomposition
Nemaura Medical Inc
| Current Assets | 4.4m |
| Cash & Short-Term Investments | 137.4k |
| Receivables | 247.8k |
| Other Current Assets | 4m |
| Non-Current Assets | 796.7k |
| PP&E | 558.7k |
| Intangibles | 238k |
| Current Liabilities | 23m |
| Accounts Payable | 352.5k |
| Accrued Liabilities | 281.1k |
| Other Current Liabilities | 22.4m |
Earnings Waterfall
Nemaura Medical Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-9.9m
USD
|
|
Operating Income
|
-9.9m
USD
|
|
Other Expenses
|
-700.2k
USD
|
|
Net Income
|
-10.6m
USD
|
Free Cash Flow Analysis
Nemaura Medical Inc
NMRD Profitability Score
Profitability Due Diligence
Nemaura Medical Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Nemaura Medical Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
NMRD Solvency Score
Solvency Due Diligence
Nemaura Medical Inc's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Score
Nemaura Medical Inc's solvency score is 23/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NMRD Price Targets Summary
Nemaura Medical Inc
Ownership
NMRD Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
NMRD Price
Nemaura Medical Inc
| Average Annual Return | -23.87% |
| Standard Deviation of Annual Returns | 46.66% |
| Max Drawdown | -100% |
| Market Capitalization | 1.9m USD |
| Shares Outstanding | 28 900 000 |
| Percentage of Shares Shorted | 0.31% |
Company Profile
Nemaura Medical Inc
Country
Industry
Market Cap
Dividend Yield
Description
Nemaura Medical, Inc. operates as a holding company. The company is headquartered in New York City, New York and currently employs 25 full-time employees. The company went IPO on 2014-11-04. The firm is focused on developing sugarBEAT, which is a non-invasive, glucose monitoring system, for use by persons with Type I and Type II diabetes and used to screen pre-diabetic patients. SugarBEAT consists of disposable adhesive skin-patch containing a sensor, which is connected to a rechargeable wireless transmitter.The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor .The sensor takes a measurement of the glucose reading every five minutes and sends the data by low energy blue tooth to a smart device such as mobile phone (both android and iOS).The data is recorded on the app and can be viewed in real time as well as storing all historic data for later evaluation as desired. The firm's subsidiaries include Region Green Limited.
You don't have any saved screeners yet
